Diagnostic and Prognostic Value of IL-10, FABP2 and LPS Levels in HCC Patients

Medicina (Kaunas). 2023 Dec 17;59(12):2191. doi: 10.3390/medicina59122191.

Abstract

Hepatocellular carcinoma (HCC) still lacks valuable diagnostic and prognostic tools. This study aimed to investigate the potential diagnostic and prognostic value of baseline interleukin (IL)-10, fatty acid-binding protein 2 (FABP2) and lipopolysaccharide (LPS) levels in patients with HCC. Serum levels of IL-10, FABP2 and LPS in 47 newly diagnosed HCC patients and 50 healthy individuals were estimated and compared. The best cut-off points for baseline IL-10, FABP2 and LPS levels predicting overall survival (OS) were evaluated. Both levels of FABP2 and IL-10 were significantly higher in HCC patients vs. control group (median 2095 vs. 1772 pg/mL, p = 0.026; 9.94 vs. 4.89 pg/mL, p < 0.001) and may serve as potential biomarkers in complex HCC diagnostic tools. The cut-off value of 2479 pg/mL for FABP2 was determined to have the highest sensitivity (66.7%) and specificity (55.6%) to distinguish patients with a median OS longer than 17 months. However, the median OS of patients with high and low levels of FABP2 were not significantly different (p = 0.896). The prognostic value of LPS as well as FABP2 and IL-10 for HCC patients appears to be limited.

Keywords: FABP2; HCC; IL-10; LPS; biomarker; hepatocellular carcinoma; prognosis.

MeSH terms

  • Biomarkers, Tumor
  • Carcinoma, Hepatocellular* / diagnosis
  • Fatty Acid-Binding Proteins
  • Humans
  • Interleukin-10
  • Lipopolysaccharides
  • Liver Neoplasms* / diagnosis
  • Prognosis

Substances

  • Lipopolysaccharides
  • Interleukin-10
  • Biomarkers, Tumor
  • Fatty Acid-Binding Proteins
  • FABP2 protein, human

Grants and funding

This research received no external funding.